Cargando…

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder

Detalles Bibliográficos
Autores principales:	Haider, Miqdad, Shafqat, Muhammad Nabeel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633328/ https://www.ncbi.nlm.nih.gov/pubmed/29042779 http://dx.doi.org/10.2147/NDT.S148952

Ejemplares similares

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga, Atsushi, et al.
Publicado: (2017)

Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
por: Kuga, Atsushi, et al.
Publicado: (2019)

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga, Atsushi, et al.
Publicado: (2017)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Subcutaneous to visceral fat ratio: a possible risk factor for metabolic syndrome and cardiovascular diseases
por: Shafqat, Muhammad Nabeel, et al.
Publicado: (2018)

Impact of air pollution on severe acute exacerbation of COPD
por: Haider, Miqdad, et al.
Publicado: (2018)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

Learning from negative feedback in patients with major depressive disorder is attenuated by SSRI antidepressants
por: Herzallah, Mohammad M., et al.
Publicado: (2013)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine
por: Tokuoka, Hirofumi, et al.
Publicado: (2017)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder
por: Young, Kymberly D., et al.
Publicado: (2020)

Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trials
por: Harada, Eiji, et al.
Publicado: (2015)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine
por: Schneider, Edith, et al.
Publicado: (2011)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Clinical characteristics associated with the prescribing of SSRI medication in adolescents with major unipolar depression
por: Cousins, Lesley, et al.
Publicado: (2016)

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
por: Lee, Min-Soo, et al.
Publicado: (2012)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

Duloxetine in panic disorder with somatic gastric pain
por: Preve, Matteo, et al.
Publicado: (2013)

Pharmacy and Medical Costs Associated With Switching Between Venlafaxine and SSRI Antidepressant Therapy for the Treatment of Major Depressive Disorder
por: Khandker, Rezaul K., et al.
Publicado: (2008)

Plasma concentrations of SSRI/SNRI after bariatric surgery and the effects on depressive symptoms
por: Pasi, Patrick, et al.
Publicado: (2023)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada, Eiji, et al.
Publicado: (2016)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

A Treatment-Response Comparison Study of Resting-State Functional Magnetic Resonance Imaging Between Standard Treatment of SSRI and Standard Treatment of SSRI Plus Non-dominant Hand-Writing Task in Patients With Major Depressive Disorder
por: Boyraz, Rabia Kevser, et al.
Publicado: (2021)

Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications
por: Maund, Emma, et al.
Publicado: (2014)

Strategy to Accelerate or Augment the Antidepressant Response and for An Early Onset of SSRI Activity. Adjunctive Amisulpride to Fluvoxamine in Major Depressive Disorder
por: Hardoy, Maria Carolina, et al.
Publicado: (2010)

The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls
por: Seiger, R, et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

New treatment options for fibromyalgia: critical appraisal of duloxetine
por: Üçeyler, Nurcan, et al.
Publicado: (2008)

The impacts of migraine and anxiety disorders on painful physical symptoms among patients with major depressive disorder
por: Hung, Ching-I, et al.
Publicado: (2014)

Ssri-treated psychiatric disorders prediction with AI
por: Mereu, A.
Publicado: (2021)

Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management
por: Jaracz, Jan, et al.
Publicado: (2016)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
por: Wohlreich, Madelaine M, et al.
Publicado: (2004)

Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study
por: Maund, Emma, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r1bf2p1s4pibpj1vf0n2mecunq